e-Drug3D

2108

DANICOPAN

INN
DANICOPAN

cas 1903768-17-1

CLASS

IMMUNOSUPPRESSANTS
COMPLEMENT FACTOR D INHIBITOR
TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
PREVENTS THE CLEAVAGE OF COMPLEMENT FACTOR B INTO THE BA AND BB FRAGMENTS

ROUTE (list)

ORAL

ATC code

L04AJ09

PK parameters

Tmax 3.7 HOUR
VD 395 LITER
Cl 63 LITER / HOUR
PPB 92.9 PERCENT
t1/2 7.9 HOUR

Solubility

INSOLUBLE FROM PH 4 TO PH 7

Target

TARGET COMPLEMENT FACTOR D

DrugCentral

Download SDF file

2-Pyrrolidinecarboxamide, 1-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoro-, (2S,4R)- (ACI)

Formula:
C26H23BrFN7O3

Calculated chemical properties:

MW 580.41
NB_atoms 38
XLogP 3.74
PSA 105.169
NB_HD 1
NB_HA 10
fsp3 0.27
Lipinski(0=no;1=yes) 0

FDA
NDA 218037 (pdf not found) INN (DANICOPAN) VOYDEYA (ALEXION PHARMS INC) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY